Investing.com — CureVac NV (NASDAQ:CVAC) tumbled almost 13% after Reuters reported the European Medicines Agency is unlikely to make a decision on its vaccine before August.
German health minister Jens Spahn provided the update on the EMA’s view on the timing of the review on Monday in a call with his regional state counterparts, Reuters said, citing a source at the health ministry familiar with the matter.
In November, CureVac secured a deal to provide up to 405 million doses of the vaccine to the EU, followed by a memorandum of understanding with Germany for another 20 million doses. Those deals hinge on approval from the EMA.
CureVac already delayed guidance on its initial testing results.